| Jennifer R Pollack, LCSW | |
|
110 Main Ave, Passaic, NJ 07055-4427 | |
| (973) 777-7638 | |
| (973) 777-9311 |
| Full Name | Jennifer R Pollack |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 33 Years |
| Location | 110 Main Ave, Passaic, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083201859 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 44SC05855600 (New Jersey) | Primary |
| Entity Name | Jewish Family Service & Childrens Center Of Clifton-passaic, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073885026 PECOS PAC ID: 3678749223 Enrollment ID: O20120103000126 |
News Archive
A study published on the British Medical Journal website shows for the first time that breathing other people's smoke raises the risk of developing glucose intolerance, the precursor to diabetes.
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.
New research suggests that not everyone who is bitten by a malaria-infected mosquito develops life threatening health problems according to scientists at the University of Toronto.
The 19 Michigan health care providers were identified as the top primary care offices through a rigorous selection process that was based on Health Plan of Michigan's 2009 quality incentive plan. "We wanted to show our gratitude to our highest ranking health care providers for their excellence in quality and service," said Raymond D. Pitera, Vice President of Provider Service for Health Plan of Michigan. "We truly appreciate the access to quality services they provide to our Medicaid Members."
AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib.
› Verified 7 days ago
| Entity Name | Rachel Pollack Lcsw Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902561137 PECOS PAC ID: 8820488851 Enrollment ID: O20211207001656 |
News Archive
A study published on the British Medical Journal website shows for the first time that breathing other people's smoke raises the risk of developing glucose intolerance, the precursor to diabetes.
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.
New research suggests that not everyone who is bitten by a malaria-infected mosquito develops life threatening health problems according to scientists at the University of Toronto.
The 19 Michigan health care providers were identified as the top primary care offices through a rigorous selection process that was based on Health Plan of Michigan's 2009 quality incentive plan. "We wanted to show our gratitude to our highest ranking health care providers for their excellence in quality and service," said Raymond D. Pitera, Vice President of Provider Service for Health Plan of Michigan. "We truly appreciate the access to quality services they provide to our Medicaid Members."
AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer R Pollack, LCSW 217 Howard Ave, Passaic, NJ 07055-4511 Ph: (973) 985-8462 | Jennifer R Pollack, LCSW 110 Main Ave, Passaic, NJ 07055-4427 Ph: (973) 777-7638 |
News Archive
A study published on the British Medical Journal website shows for the first time that breathing other people's smoke raises the risk of developing glucose intolerance, the precursor to diabetes.
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test v2, a blood-based companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.
New research suggests that not everyone who is bitten by a malaria-infected mosquito develops life threatening health problems according to scientists at the University of Toronto.
The 19 Michigan health care providers were identified as the top primary care offices through a rigorous selection process that was based on Health Plan of Michigan's 2009 quality incentive plan. "We wanted to show our gratitude to our highest ranking health care providers for their excellence in quality and service," said Raymond D. Pitera, Vice President of Provider Service for Health Plan of Michigan. "We truly appreciate the access to quality services they provide to our Medicaid Members."
AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib.
› Verified 7 days ago
Alexander Fleischer, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 412 Brook Ave, Passaic, NJ 07055 Phone: 917-213-0749 | |
Ms. Abril Lazaro, LSW, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 110 Main Ave, Passaic, NJ 07055 Phone: 973-777-7638 | |
Suzanne L Miller, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 110 Main Ave, Passaic, NJ 07055 Phone: 973-777-7638 Fax: 973-777-9311 | |
Dr. Simon Y Feuerman, PSYD, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 200 Main Ave, Suite B, Passaic, NJ 07055 Phone: 973-249-8111 | |
Rivkah Weldler, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 110 Main Ave, Passaic, NJ 07055 Phone: 973-777-7638 | |
Lisa Ann Lussier, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 85 Crescent Ave, Passaic, NJ 07055 Phone: 973-264-0022 | |
Kelly Eid, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 85 Crescent Ave, Passaic, NJ 07055 Phone: 973-264-0023 |